Fernandes Susan, Williams Elvira, Finlayson Neil, Stewart Hazel, Dhaliwal Catharine, Dorward David A, Wallace William A, Akram Ahsan R, Stone James, Dhaliwal Kevin, Williams Gareth O S
Translational Healthcare Technologies Group, Centre for Inflammation Research, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
Department of Respiratory Medicine, NHS Lothian, Royal Infirmary of Edinburgh, Edinburgh, UK.
Transl Lung Cancer Res. 2024 Feb 29;13(2):355-361. doi: 10.21037/tlcr-23-638. Epub 2024 Feb 28.
Lung cancer is the most common cause of cancer-related deaths worldwide. Early detection improves outcomes, however, existing sampling techniques are associated with suboptimal diagnostic yield and procedure-related complications. Autofluorescence-based fluorescence-lifetime imaging microscopy (FLIM), a technique which measures endogenous fluorophore decay rates, may aid identification of optimal biopsy sites in suspected lung cancer. Our fibre-based fluorescence-lifetime imaging system, utilising 488 nm excitation, which is deliverable via existing diagnostic platforms, enables real-time visualisation and lifetime analysis of distal alveolar lung structure. We evaluated the diagnostic accuracy of the fibre-based fluorescence-lifetime imaging system to detect changes in fluorescence lifetime in freshly resected lung cancer and adjacent healthy tissue as a first step towards future translation. The study compares paired non-small cell lung cancer (NSCLC) and non-cancerous tissues with gold standard diagnostic pathology to assess the performance of the technique. Paired NSCLC and non-cancerous lung tissues were obtained from thoracic resection patients (N=21). A clinically compatible 488 nm fluorescence-lifetime endomicroscopy platform was used to acquire simultaneous fluorescence intensity and lifetime images. Fluorescence lifetimes were calculated using a computationally-lightweight, rapid lifetime determination method. Fluorescence lifetime was significantly reduced in lung cancer, compared with non-cancerous lung tissue [mean ± standard deviation (SD), 1.79±0.40 . 2.15±0.26 ns, P<0.0001], and fluorescence intensity images demonstrated distortion of alveolar elastin autofluorescence structure. Fibre-based fluorescence-lifetime imaging demonstrated good performance characteristics for distinguishing lung cancer, from adjacent non-cancerous tissue, with 81.0% sensitivity and 71.4% specificity. Our novel fibre-based fluorescence-lifetime imaging system, which enables label-free imaging and quantitative lifetime analysis, discriminates lung cancer from adjacent healthy tissue. This minimally invasive technique has potential to be translated as a real-time biopsy guidance tool, capable of optimising diagnostic accuracy in lung cancer.
肺癌是全球癌症相关死亡的最常见原因。早期检测可改善治疗结果,然而,现有的采样技术存在诊断率不理想和与操作相关的并发症等问题。基于自体荧光的荧光寿命成像显微镜(FLIM)是一种测量内源性荧光团衰减率的技术,可能有助于在疑似肺癌中识别最佳活检部位。我们基于光纤的荧光寿命成像系统利用488nm激发光,可通过现有的诊断平台进行传输,能够对远端肺泡肺结构进行实时可视化和寿命分析。作为未来转化的第一步,我们评估了基于光纤的荧光寿命成像系统检测新鲜切除的肺癌及相邻健康组织中荧光寿命变化的诊断准确性。该研究将配对的非小细胞肺癌(NSCLC)组织和非癌组织与金标准诊断病理学进行比较,以评估该技术的性能。从胸段切除术患者中获取配对的NSCLC和非癌肺组织(N = 21)。使用临床兼容的488nm荧光寿命内镜平台同时采集荧光强度和寿命图像。使用计算轻量级、快速寿命测定方法计算荧光寿命。与非癌肺组织相比,肺癌中的荧光寿命显著缩短[平均值±标准差(SD),1.79±0.40 . 2.15±0.26 ns,P<0.0001],并且荧光强度图像显示肺泡弹性蛋白自体荧光结构变形。基于光纤的荧光寿命成像在区分肺癌与相邻非癌组织方面表现出良好的性能特征,灵敏度为81.0%,特异性为71.4%。我们新型的基于光纤的荧光寿命成像系统能够进行无标记成像和定量寿命分析,可区分肺癌与相邻健康组织。这种微创技术有潜力转化为实时活检引导工具,能够优化肺癌的诊断准确性。